Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TYMS | P04818 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 5/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10460758 | 0.89 | EGFR (0.48) | MAPK1ALDH1A1LMNATHRBTSHR | |
| SCHEMBL11824972 | 0.82 | EGFR (0.58) | ALDH1A1EGFRERBB2GLASMN1; SMN2 | |
| SCHEMBL11845539 | 0.81 | MAPT (0.48) | MAPK1ALDH1A1LMNATHRBTSHR | |
| SCHEMBL11834463 | 0.79 | CA1 (0.53) | MAPK1ALDH1A1LMNATHRBTSHR | |
| SCHEMBL2558351 | 0.79 | TYMS (0.47) | MAPK1ALDH1A1LMNATHRBTSHR | |
| Metronidazole SCHEMBL2670090 | 0.76 | LMNA (0.94) | MAPK1ALDH1A1LMNATHRBTSHR | |
| Metronidazole SCHEMBL23042 | 0.75 | LMNA (1.00) | MAPK1ALDH1A1LMNATHRBTSHR | |
| Metronidazole SCHEMBL9455119 | 0.75 | LMNA (1.00) | MAPK1ALDH1A1LMNATHRBTSHR | |
| Metronidazole SCHEMBL9482744 | 0.75 | LMNA (1.00) | MAPK1ALDH1A1LMNATHRBTSHR | |
| Metronidazole SCHEMBL5313560 | 0.75 | LMNA (1.00) | MAPK1ALDH1A1LMNATHRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307577-A | Symmetrical and unsymmetrical substituted dipyrazole boron compound and preparation thereof | 华南理工大学 | 2024-07-09 | — | — | CN | claimed |
| US-11679118-B2 | Parasite therapy | BORODY THOMAS J (AU) | 2023-06-20 | — | — | US | claimed |
| CN-111921539-B | Ni-Ru/GO bimetallic catalyst and preparation method thereof | 广东工业大学 | 2022-11-11 | — | — | CN | claimed |
| CN-113456670-B | Indole derivative-silver composite nano-particles, preparation method thereof and application of indole derivative-silver composite nano-particles as antibacterial material | 太原理工大学 | 2022-08-16 | — | — | CN | claimed |
| US-20220184101-A1 | PARASITE THERAPY | BORODY THOMAS J (AU) | 2022-06-16 | — | — | US | claimed |
| US-11241447-B2 | Parasite therapy | Borody, Thomas Julius (AU) | 2022-02-08 | — | — | US | claimed |
| US-20200069705-A1 | NOVEL PARASITE THERAPY | BORODY THOMAS J (AU) | 2020-03-05 | — | — | US | claimed |
| US-20170202862-A9 | NOVEL PARASITE THERAPY | BORODY THOMAS J (AU) | 2017-07-20 | — | — | US | claimed |
| US-20160256476-A1 | NOVEL PARASITE THERAPY | BORODY THOMAS J (AU) | 2016-09-08 | — | — | US | claimed |
| US-9364464-B2 | Compositions and methods for treating extracellular parasitic infections | BORODY THOMAS J (AU) | 2016-06-14 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| WO-2005058282-A1 | DOUBLE PELLET FORMULATION OF PROTON PUMP INHIBITORS AND CLARITHROMYCIN FOR THE TREATMENT OF GASTROINTESTINAL ULCER, AND METHOD FOR PRODUCING THE SAME | KOREA UNITED PHARM, INC (KR) | 2005-06-30 | — | — | WO | claimed |
| CN-1147292-C | Double capsule for the administration of active principles in multiple therepies | ������ҩ������˾ | 2004-04-28 | — | — | CN | claimed |
| EP-1037614-B1 | A DOUBLE CAPSULE FOR THE ADMINISTRATION OF ACTIVE PRINCIPLES IN MULTIPLE THERAPIES | AXCAN PHARMA INC (CA) | 2003-11-26 | — | — | EP | claimed |
| US-6350468-B1 | ORALLY ADMINISTERING TO MAMMAL DOSAGE FORM COMPRISING INTERNAL CAPSULE COMPRISING ANTIBIOTIC PLACED INSIDE EXTERNAL CAPSULE COMPRISING SOLUBLE BISMUTH SALT AND SECOND ANTIBIOTIC; TRIPLE THERAPY AGAINST MICROORGANISM HELICOBACTER PYLORI | AXCAN PHARMA INC. (CA) | 2002-02-26 | — | — | US | claimed |
| CN-1285741-A | Double-layer capsule for administering active ingredients in combination therapy | AXCAN PHARMA INC (CA) | 2001-02-28 | — | — | CN | claimed |
| EP-1037614-A2 | A DOUBLE CAPSULE FOR THE ADMINISTRATION OF ACTIVE PRINCIPLES IN MULTIPLE THERAPIES | Axcan Pharma Inc. (CA) | 2000-09-27 | — | — | EP | claimed |
| WO-1999030693-A2 | A DOUBLE CAPSULE FOR THE ADMINISTRATION OF ACTIVE PRINCIPLES IN MULTIPLE THERAPIES | AXCAN PHARMA INC. (CA) | 1999-06-24 | — | — | WO | claimed |
| US-3941801-A | Process for preparing substituted nitroimidazoles | MERCK & CO., INC. (US) | 1976-03-02 | — | — | US | claimed |